On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) Enrolls First Patient in Phase 2b Trial of EGP-437 for Cataract Surgery

Company: EyeGate Pharmaceuticals, Inc. (EYEG)
Category: News

Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are down 8% in mid-day trade. The specialty pharmaceutical company this morning said it has enrolled the first patient in the phase 2b clinical trial to evaluate its EyeGate® II Delivery System and EGP-437 combination product for the treatment of pain and inflammation in patients that have undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens). Top-line data is anticipated by year-end 2017. Under an exclusive worldwide licensing agreement signed with Valeant Pharmaceuticals International, Inc. (NYSE: VRX) earlier this year, a subsidiary of Valeant has commercial and manufacturing rights to the EGP-437 combination product candidate for the treatment of post-operative ocular inflammation and pain in ocular surgery patients. Once approved, Valeant intends to commercialize the combination product through its Bausch + Lomb Pharmaceuticals business. “This trial will allow us to better understand the clinical benefit patients are receiving from this therapy, and to support its role in the management of pain and inflammation, common side effects following cataract surgery. We are thrilled to have taken this significant step toward advancing the development of the EGP-437 combination product in this significant ophthalmic market,” EyeGate president and CEO Stephen From stated in the news release.

To view the full press release, visit: http://nnw.fm/lU4Ma

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

About EyeGate:

EyeGate is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing products for treating diseases and disorders of the eye. EyeGate is developing products using CMHA-S, a modified form of the natural polymer hyaluronic acid (HA), which possesses unique physical and chemical properties such as hydration and healing properties. The ability of CMHA-S to adhere longer to the ocular surface, resist degradation and protect the ocular surface makes it well-suited for treating various ocular surface injuries.,EGP-437, EyeGate’s other product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System. For more information, please visit www.EyeGatePharma.com.

More from CannabisNewsBreaks

Skyline Medical, Inc. (NASDAQ: SKLN) Inks Binding LOI for Merger Transaction with CytoBioscience

SinglePoint, Inc. (SING) Sees Continued Momentum with Plans to Develop Bitcoin Payment Solution

India Globalization Capital, Inc. (NYSE: IGC) Adds Dr. Chuanhai Cao to Medical Research Team

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.cannabisnewswire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, CO
www.cannabisnewswire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722